Article Listing - Merck & Co confirms NDA filing for suvorexant in 2012

ICH STEERING COMMITTEE MEETING

6 April 1992

The Steering Committee for the Second International Conference on Harmonization (ICH) of technical requirements for the registration of pharmaceutical products...

STOCK MARKET COMMENTARY: TOKYO

6 April 1992

TOKYO: stocks declined last week after a brief hiatus. The Nikkei Average fell 2.8% to 19,669.311, once again below the...

US MEDICAID REBATES AND "BEST PRICES"

6 April 1992

Eliminating the "best price" provision from the US Medicaid rebate formula for the top 100 single-source and innovator multiple-source drugs...

US FDA USER FEES: "THE TIME HAS COME"

6 April 1992

People in the US Food and Drug Administration-regulated industries now recognize that the time has arrived for user fees to...

ICN HUBBER GROUP IN SPAIN

6 April 1992

The ICN Hubber Group is investing 1.7 billion pesetas ($2.2 million) in a new pharmaceutical plant near Barcelona in Spain....

NEW PRES AT PROCORDIA

6 April 1992

Jan Ekberg has been named as president and chief executive at Procordia, in succession to Soren Gyll who has become...

PHARMA COs TOP R&D SPEND IN JAPAN

6 April 1992

Of 16 Japanese companies planning to spend over 10% of their sales on R&D in 1992, nine are pharmaceutical companies,...

US HOSPITAL FORMULARY GUIDE

6 April 1992

The American Society of Hospital Pharmacists has released guidelines on formulary system management for its members.

The ASHP notes that in...

GALLUP SURVEYS UK GPs ON HEPATITIS A

6 April 1992

With the recent introduction of its hepatitis A vaccine Havrix to the UK market, SmithKline Beecham has sponsored a Gallup...

GENENTECH REBUFFS ISIS-3 AND AWAITS GUSTO

6 April 1992

With the formal publication in The Lancet last week of the results of the ISIS-3 thrombolytic product trial, the major...